Other Targetable Sarcomas

Pires de Camargo, Veridiana; van de Rijn, Matt; de Alava, Enrique; Madoz-Gúrpide, Juan; Pilotti, Silvana; von Mehren, Margaret; Pedeutour, Florence; Maki, Robert G.; Rutkowski, Piotr; Thomas, David M.

doi:10.1053/j.seminoncol.2009.06.008

« PreviousSeminars in Oncology
Volume 36, Issue 4 , Pages 358-371, August 2009

Other Targetable Sarcomas Disclosures

Veridiana Pires de Camargo
- Sarcoma Program, Memorial Sloan-Kettering Cancer Center, New York, NY
- These authors contributed equally to this work.
Matt van de Rijn
- Department of Pathology, Stanford University Medical Center, Stanford, CA
- These authors contributed equally to this work.
Enrique de Alava
- Molecular Pathology Program, Centro de Investigación del Cáncer–IBMCC, University of Salamanca–CSIC, Salamanca, Spain
- These authors contributed equally to this work.
Juan Madoz-Gúrpide
- Molecular Pathology Program, Centro de Investigación del Cáncer–IBMCC, University of Salamanca–CSIC, Salamanca, Spain
- These authors contributed equally to this work.
Silvana Pilotti
- Laboratory of Experimental Molecular Pathology, Department of Pathology, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy
- These authors contributed equally to this work.
Margaret von Mehren
- Sarcoma Oncology, Fox Chase Cancer Center, Philadelphia, PA
- These authors contributed equally to this work.
Florence Pedeutour
- Laboratoire de Génétique des Tumeurs Solides, Faculté de Médecine, Centre Hospitalier Universitaire de Nice et CNRS UMRS 6543, Nice, France
- These authors contributed equally to this work.
Robert G. Maki
- Sarcoma Program, Memorial Sloan-Kettering Cancer Center, New York, NY
- These authors contributed equally to this work.
Piotr Rutkowski
- Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Department of Soft Tissue/Bone Sarcoma and Melanoma, Warsaw, Poland
- These authors contributed equally to this work.
David M. Thomas
- Research Division, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
- These authors contributed equally to this work.
- Address correspondence to David M. Thomas, FRACP, PhD, Research Division, Peter MacCallum Cancer Centre, St Andrew's Place, East Melbourne, Victoria 3002, Australia

Despite complex genetics, aneuploid tumors like dedifferentiated liposarcoma have specific and reproducible chromosomal changes such as amplification of HDM2 and CDK4 that represent potential targets for systemic therapy. In addition, there are cancer cell survival pathways that may not be the target of chromosomal translocations or mutations that are still estimable targets for new systemic therapeutics, be it pathways involved in angiogenesis or apoptosis. In this review, we examine target selection for specific sarcoma subtypes, and demonstrate with a few examples new techniques being used to delineate novel therapeutic inroads for patients with sarcoma.

To access this article, please choose from the options below

Enrique de Alava is supported by the European Commission (NoE EuroBoNet), Ministry of Science and Innovation of Spain-FEDER (PI052524, RD06/0020/0059). Silvana Pilotti is supported by Associazione Italiana per la Ricerca sul Cancro (AIRC). Robert G. Maki is supported by Program Project Grant No. P01-CA47179; Cycle for Survival. David M. Thomas is supported by the Victorian Cancer Agency Clinician Researcher fellowship, and Cancer Australia.

Disclosures Robert G. Maki: Research support (Pfizer); honoraria (Ziopharm); testimony (Roche)Margaret von Mehren: Research support (Novartis, Pfizer, Johnson & Johnson); consultation fees (Novartis, Pfizer, Medimmune)David Thomas: Research support (Novartis, Amgen, Pfizer)

PII: S0093-7754(09)00108-0

doi:10.1053/j.seminoncol.2009.06.008